Stefano Colombo

We are proud to announce Omega Pharma's acquisition of Cieffe Derma, an Italian company specialized in the development and commercialization of scientifically-supported products with a particular focus on dermatology. This acquisition represents Omega’s second add-on in the nutraceutical sector since joining 21 Invest’s portfolio in February 2024, following the acquisition of Inpha in December 2024. Thanks to the acquisition of Cieffe Derma, Omega Pharma aims to exceed €M 40 in revenue in 2025, with a network of around 200 scientific representatives operating throughout Italy. Andrea Mazzucato, Stefano De Rossi, Massimo Galli, Valentina Mattiussi Omega Pharma SRL, Cieffe Derma

123

1 commento

We are pleased to announce that the European Medicines Agency has issued a positive opinion for the HIPRA's adjuvanted recombinant protein vaccine adapted to the LP.8.1 variant, for use in the 2025-2026 vaccination campaign. Produced entirely in Spain, the vaccine aligns with EMA and World Health Organization recommendations. This achievement underscores HIPRA's commitment to building immunity for a healthier world. #HIPRA #COVID19 #vaccines #globalhealth #prevention

389

6 commenti

This week, dedicated ALK employees are attending the annual Global Food Allergy and Anaphylaxis Forum to shed light on these important disease areas. 🌍 The influential conference, organised by the Global Allergy and Asthma Excellence Network and hosted in Padua, Italy, provides a vital platform for collaboration and innovation in the field of food allergy and anaphylaxis management. With over 100 years of innovation in the allergy field, three decades of experience in anaphylaxis and a strategic ambition to help more people with food allergy, our colleagues have joined the conference with lots of knowledge and a symposium showcasing our latest insights and experiences in the treatment of anaphylaxis. Additionally, we’re presenting an oral abstract presentation on a digital alternative to the traditional, physical training methods for adrenaline treatment, focusing on effective education of people at risk of the potentially life-threatening anaphylactic shock, which can be triggered by for instance food allergy. At ALK, we are committed to advancing our understanding of food allergies and anaphylaxis and to ensuring that we reach those who need it the most – this conference provided another vital opportunity for this.

135

A new £4.9m clinical trial will test whether fusidic acid, a widely used antibiotic, can be repurposed as a short-course cure for onchocerciasis (river blindness). The FAME (Fusidic Acid Macrofilaricide Evaluation) trial is coordinated by the Centre for Drugs and Diagnostics and the Centre for Neglected Tropical Diseases, working in partnership with the University of Buea in Cameroon, The University of Bonn in Germany, and the Drugs for Neglected Diseases initiative (DNDi) in Switzerland. Funded by the European & Developing Countries Clinical Trials Partnership (EDCTP), the trial will evaluate whether fusidic acid can serve as a quicker but equally effective alternative to existing treatments, thereby helping to accelerate elimination and reduce the burden on affected communities. Read more: https://lnkd.in/eRvtwC4b

137

3 commenti